Enhanced Anti-Mycobacterial Drugs with Modified Backbone Structures

The inventive concept relates to novel oligo(carbamoylated guanidine) (OCG) compounds with modified backbone structures, enhancing their ability to treat mycobacterial infections, including tuberculosis, more effectively and efficiently.

The current TB treatment regimen is lengthy and rigorous due to difficulties associated with the existing OCGs. The inventive concept addresses these limitations by introducing modified backbone structures, enhancing the OCGs' ability to dissipate a component of the proton motive force (PMF) and deplete ATP production, thereby improving their bactericidal effects.

The new OCG compounds feature modified backbone structures, including cationic ends designed to interact with the bacterial cell membrane, enhancing their bactericidal effects. The inventive concept also encompasses methods for treating mycobacterial infections, systems for inhibiting mycobacterial growth, and pharmaceutical formulations for oral administration of OCGs with pH-sensitive coatings. These enhancements provide a synergistic effect in inhibiting mycobacterial growth, increasing the selectivity of OCGs towards mycobacterial cells, and improving their bioavailability in the gastrointestinal tract.

The new claims introduce novel modifications to the OCG backbone structure, enhancing their ability to treat mycobacterial infections. These modifications are non-obvious compared to the original patent, as they require a deep understanding of the OCG's mechanism of action and the specific limitations of the existing treatment regimen.

Other embodiments of the inventive concept could include modifying the H-bonding pattern of the OCG to increase its specificity towards mycobacterial cells, or combining OCGs with different backbone structures to provide a synergistic effect. Additionally, the inventive concept could be adapted for use in treating other bacterial infections, such as MRSA or E. coli.

The enhanced anti-mycobacterial drugs have significant commercial potential in the pharmaceutical industry, particularly in the development of new treatments for tuberculosis and other bacterial infections. The target market includes pharmaceutical companies, research institutions, and healthcare organizations focused on infectious disease treatment and prevention.